Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009
Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances
Dept Health & Human Services (Apr), FDA Public Health Advisory, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Complications of Intravenous Immune Globulin Treatment in Neurologic Disease
Neurol 47:674-677, Brannagan III,T.H.,et al, 1996
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Thiamine Deficiency in Patients with Congestive Heart Failure Receiving Long-Term Furosemide Therapy:A Pilot Study
Am J Med 91:151-155, Seligmann,H.,et al, 1991
Irregular Breathing
In Internal Medicine, Little, Brown & Co, Boston, 3rd Ed, p. 573-574, Cherniack,N.S., 1990